Teva Pharmaceutical Industries Ltd (TEVA) Stock Analysis and Metrics

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic CIK: 0000818686

Market Cap 32.45 Bn

P/E 22.85

P/S 1.88

Div. Yield 0.00

ROIC (Qtr) 0.29

Total Debt (Qtr) 16.81 Bn

Revenue Growth (1y) (Qtr) 62.45

Add ratio to table...

About

Teva Pharmaceutical Industries Ltd., or TEVA, is a global pharmaceutical company that specializes in the generic, innovative, and biopharmaceutical markets. Established in Israel in 1944, TEVA has grown to become a prominent player in the pharmaceutical industry with a mission to provide affordable medicines and innovative health solutions to patients worldwide. The company is organized into three segments: North America, Europe, and International Markets. The North America segment includes the United States and Canada, while the Europe segment...

Teva Pharmaceutical Industries Ltd., or TEVA, is a global pharmaceutical company that specializes in the generic, innovative, and biopharmaceutical markets. Established in Israel in 1944, TEVA has grown to become a prominent player in the pharmaceutical industry with a mission to provide affordable medicines and innovative health solutions to patients worldwide.

The company is organized into three segments: North America, Europe, and International Markets. The North America segment includes the United States and Canada, while the Europe segment includes the European Union, the United Kingdom, and other European countries. The International Markets segment covers over 35 countries, making up a significant portion of the global pharmaceutical industry.

TEVA's primary products include generic medicines, biopharmaceuticals, innovative medicines, over-the-counter (OTC) products, and active pharmaceutical ingredients (APIs). TEVA's generic medicines business is committed to delivering high-quality and affordable medicines to patients, with a portfolio of over 500 generic prescription products in more than 1,400 dosage strengths, packaging sizes, and forms. The company's innovative medicines portfolio includes products such as AUSTEDO, AJOVY, UZEDY, and COPAXONE. AUSTEDO is a deuterated form of a small molecule inhibitor of vesicular monoamine 2 transporter (VMAT2) that regulates the levels of dopamine in the brain. AJOVY is a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and is used for the preventive treatment of migraine in adults. UZEDY is a subcutaneous, long-acting formulation of risperidone that controls the steady release of risperidone. COPAXONE is a glatiramer acetate injection used for the treatment of patients with relapsing forms of multiple sclerosis (MS).

TEVA's biopharmaceuticals business focuses on developing and commercializing biosimilars, which are highly similar to the reference biologic in both structure and function. The company has launched several biosimilars, including Truxima, Herzuma, and Ranivisio. TEVA's OTC products business is focused on developing and commercializing a range of OTC products, such as SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA. TEVA's APIs business focuses on developing and commercializing a range of APIs, which are used as active ingredients in the manufacture of pharmaceutical products.

TEVA's competitive advantages include its global presence, diversified product portfolio, and strong pipeline of innovative medicines and biosimilars. The company's position in the generics market is supported by its global R&D function, as well as its API R&D and manufacturing activities, which provide significant vertical integration for its products. TEVA is one of the leading generic pharmaceutical companies in the world, with a strong presence in the United States, Europe, and other regions. The company is also a significant player in the innovative medicines market, with a portfolio of products that includes AUSTEDO, AJOVY, UZEDY, and COPAXONE.

TEVA's customers include retail pharmacies, hospital pharmacies, wholesalers, and distributors. The company's products are used by patients and healthcare professionals around the world and are available in a range of formulations and strengths.

Investment thesis

Bull case

Teva’s flagship asset, AUSTEDO, delivered a 34% revenue surge, a testament to its position as a first‑line therapy for tardive dyskinesia, a disease with an estimated 800,000 patients and only 6% currently treated. The company’s emphasis on expanding the US market has translated into a 1.642 billion dollar revenue base and a projected $1.9‑$2.0 billion in 2025, underscoring a solid top‑line trajectory. Management’s confidence in the drug’s unmet medical need, coupled with a targeted $2.5 billion 2027 sales goal, signals that the product remains a cornerstone of Teva’s growth engine. Even with the IRA redesign’s immediate hit, the long runway and potential for increased penetration should buffer the short‑term impact.
The rapid performance of UZEDY and AJOVY—each exceeding guidance—demonstrates Teva’s capacity to capture niche indications with high reimbursement ceilings. UZEDY’s $117 million in 2024, surpassing the $100 million target, and AJOVY’s $0.5 billion in 2024 with 18% growth highlight the robustness of the innovative portfolio. While the Part D redesign imposes a headwind, the company’s forecast of $160 million in 2025 suggests that the redesign’s effects may be limited once the transition is complete. Moreover, the incremental revenue from these assets reinforces the company’s ability to diversify beyond Revlimid dependence.
Teva’s biosimilar strategy has progressed to 18 assets with seven US launches and four EU launches slated for 2025–2027, adding a significant high‑margin growth vector. The company’s commitment to launching 16 complex generics in 2025–2026 further widens the product mix, offering higher profit margins than traditional generics. The strategic focus on biosimilars, a sector that historically delivers above‑average profitability, positions Teva to capture market share in a rapidly consolidating market. The resulting margin expansion, combined with cost efficiencies, is expected to support a stable 53%–54% gross margin in 2025.
The divestiture of the API business, now classified as held for sale, signals Teva’s intent to streamline operations and free capital for high‑growth initiatives. The sale is expected to reduce net debt to an EBITDA ratio approaching the 2x target by 2027, aligning with the credit upgrades received from major agencies. A leaner balance sheet improves flexibility for strategic acquisitions, R&D investment, and dividend policy. The credit rating improvement reflects market confidence in Teva’s deleveraging trajectory, bolstering investor sentiment.
Teva’s R&D spend rising to above 6% of revenue in 2025 underscores a strategic pivot to innovation, aligning with the company’s “step‑up innovation” pillar. The pipeline includes duvakitug, IL15, DARI, and olanzapine, each addressing high‑unmet needs across immunology, neurology, and psychiatry. Early‑stage data for duvakitug show robust efficacy and a favorable safety profile, potentially opening multiple indications. Successful progression to Phase 3 will provide a credible upside, further diversifying revenue streams beyond the core generics business.

Teva’s flagship asset, AUSTEDO, delivered a 34% revenue surge, a testament to its position as a first‑line therapy for tardive dyskinesia, a disease with an estimated 800,000 patients and only 6% currently treated. The company’s emphasis on expanding the US market has translated into a 1.642 billion dollar revenue base and a projected $1.9‑$2.0 billion in 2025, underscoring a solid top‑line trajectory. Management’s confidence in the drug’s unmet medical need, coupled with a targeted $2.5 billion 2027 sales goal, signals that the product remains a cornerstone of Teva’s growth engine. Even with the IRA redesign’s immediate hit, the long runway and potential for increased penetration should buffer the short‑term impact.
The rapid performance of UZEDY and AJOVY—each exceeding guidance—demonstrates Teva’s capacity to capture niche indications with high reimbursement ceilings. UZEDY’s $117 million in 2024, surpassing the $100 million target, and AJOVY’s $0.5 billion in 2024 with 18% growth highlight the robustness of the innovative portfolio. While the Part D redesign imposes a headwind, the company’s forecast of $160 million in 2025 suggests that the redesign’s effects may be limited once the transition is complete. Moreover, the incremental revenue from these assets reinforces the company’s ability to diversify beyond Revlimid dependence.
Teva’s biosimilar strategy has progressed to 18 assets with seven US launches and four EU launches slated for 2025–2027, adding a significant high‑margin growth vector. The company’s commitment to launching 16 complex generics in 2025–2026 further widens the product mix, offering higher profit margins than traditional generics. The strategic focus on biosimilars, a sector that historically delivers above‑average profitability, positions Teva to capture market share in a rapidly consolidating market. The resulting margin expansion, combined with cost efficiencies, is expected to support a stable 53%–54% gross margin in 2025.
The divestiture of the API business, now classified as held for sale, signals Teva’s intent to streamline operations and free capital for high‑growth initiatives. The sale is expected to reduce net debt to an EBITDA ratio approaching the 2x target by 2027, aligning with the credit upgrades received from major agencies. A leaner balance sheet improves flexibility for strategic acquisitions, R&D investment, and dividend policy. The credit rating improvement reflects market confidence in Teva’s deleveraging trajectory, bolstering investor sentiment.
Teva’s R&D spend rising to above 6% of revenue in 2025 underscores a strategic pivot to innovation, aligning with the company’s “step‑up innovation” pillar. The pipeline includes duvakitug, IL15, DARI, and olanzapine, each addressing high‑unmet needs across immunology, neurology, and psychiatry. Early‑stage data for duvakitug show robust efficacy and a favorable safety profile, potentially opening multiple indications. Successful progression to Phase 3 will provide a credible upside, further diversifying revenue streams beyond the core generics business.

Bear case

Litigation costs have surged to $522 million in 2024, an increase of $57 million from the prior year, and the company signals that settlement outflows are expected to rise further in 2025. This incremental cash outflow reduces free cash flow, creating a liquidity strain that could force Teva to tap additional debt or suspend dividend payments. The absence of a detailed timeline for future settlements leaves investors uncertain about the magnitude of future liabilities. Consequently, escalating legal expenses pose a tangible risk to Teva’s financial health.
The Medicare Part D redesign and the IRA’s impact on AUSTEDO represent immediate revenue headwinds that were not fully quantified by management. CEO Richard Francis admitted that the IRA “hit” AUSTEDO and UZEDY “straight away,” yet no precise revenue loss or timeline for recovery was disclosed. This lack of clarity hampers investors’ ability to model short‑term cash flow impacts. The possibility of reduced uptake or reimbursement adjustments could erode the sales growth that Teva currently projects for its innovative portfolio.
Foreign exchange headwinds have already eroded revenue and gross profit in 2024, and Teva’s guidance indicates that USD strength will persist into 2025. While management acknowledges the impact, the company has not articulated a robust hedging framework to neutralize further currency swings. Without a clear mitigation strategy, Teva remains vulnerable to macro‑financial volatility that could compress margins and destabilize earnings in a dollar‑strong environment.
The classification of Teva’s API business as held for sale introduces a level of uncertainty regarding the timing and valuation of the divestiture. Management has offered limited disclosure on the expected sale price or regulatory approvals, which could delay the expected debt reduction. Prolonged uncertainty surrounding the API exit could leave Teva with higher leverage than anticipated, potentially triggering covenant breaches or necessitating additional debt financing at unfavorable terms.
R&D spending is set to increase above 6% of revenue in 2025, but the company’s pipeline includes multiple late‑stage programs that carry significant risk of clinical failure. While early data for duvakitug and other assets are promising, the transition to Phase 3 introduces higher development costs and regulatory uncertainty. Management has not provided a clear probability of success or a contingency plan for potential setbacks, raising the risk that increased R&D investment may not translate into commensurate revenue growth.

Litigation costs have surged to $522 million in 2024, an increase of $57 million from the prior year, and the company signals that settlement outflows are expected to rise further in 2025. This incremental cash outflow reduces free cash flow, creating a liquidity strain that could force Teva to tap additional debt or suspend dividend payments. The absence of a detailed timeline for future settlements leaves investors uncertain about the magnitude of future liabilities. Consequently, escalating legal expenses pose a tangible risk to Teva’s financial health.
The Medicare Part D redesign and the IRA’s impact on AUSTEDO represent immediate revenue headwinds that were not fully quantified by management. CEO Richard Francis admitted that the IRA “hit” AUSTEDO and UZEDY “straight away,” yet no precise revenue loss or timeline for recovery was disclosed. This lack of clarity hampers investors’ ability to model short‑term cash flow impacts. The possibility of reduced uptake or reimbursement adjustments could erode the sales growth that Teva currently projects for its innovative portfolio.
Foreign exchange headwinds have already eroded revenue and gross profit in 2024, and Teva’s guidance indicates that USD strength will persist into 2025. While management acknowledges the impact, the company has not articulated a robust hedging framework to neutralize further currency swings. Without a clear mitigation strategy, Teva remains vulnerable to macro‑financial volatility that could compress margins and destabilize earnings in a dollar‑strong environment.
The classification of Teva’s API business as held for sale introduces a level of uncertainty regarding the timing and valuation of the divestiture. Management has offered limited disclosure on the expected sale price or regulatory approvals, which could delay the expected debt reduction. Prolonged uncertainty surrounding the API exit could leave Teva with higher leverage than anticipated, potentially triggering covenant breaches or necessitating additional debt financing at unfavorable terms.
R&D spending is set to increase above 6% of revenue in 2025, but the company’s pipeline includes multiple late‑stage programs that carry significant risk of clinical failure. While early data for duvakitug and other assets are promising, the transition to Phase 3 introduces higher development costs and regulatory uncertainty. Management has not provided a clear probability of success or a contingency plan for potential setbacks, raising the risk that increased R&D investment may not translate into commensurate revenue growth.

Equity Components Breakdown of Revenue (2025)

Peer comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	TAK	Takeda Pharmaceutical Co Ltd	202.50 Bn	40.69	6.74	27.43 Bn
2	ZTS	Zoetis Inc.	51.58 Bn	19.29	5.45	9.04 Bn
3	TEVA	Teva Pharmaceutical Industries Ltd	32.45 Bn	22.85	1.88	16.81 Bn
4	UTHR	UNITED THERAPEUTICS Corp	26.06 Bn	19.51	8.19	-
5	ACB	Aurora Cannabis Inc	15.01 Bn	93.81	-2,482.90	0.04 Bn
6	NBIX	Neurocrine Biosciences Inc	12.80 Bn	26.69	4.47	-
7	HCM	HUTCHMED (China) Ltd	12.21 Bn	26.85	22.27	0.09 Bn
8	ELAN	Elanco Animal Health Inc	11.64 Bn	-49.87	2.47	4.02 Bn

Research Tools

Teva Pharmaceutical Industries Ltd (NYSE: TEVA)

About

Investment thesis

Bull case

Bear case

Equity Components Breakdown of Revenue (2025)

Peer comparison

Research Tools

Teva Pharmaceutical Industries Ltd (NYSE: TEVA)

About

Investment thesis

Bull case

Bear case

Equity Components Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password